Cargando…
The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are reported to be oncogenic through activating the MAPK/Erk1/2 pathway. Protein kinase C (PKC) is a component of signaling from GNAQ to Erk1/2. Inhibition of PKC might regulate GNAQ mutation-i...
Autores principales: | Wu, Xinqi, Zhu, Meijun, Fletcher, Jonathan A., Giobbie-Hurder, Anita, Hodi, F. Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257235/ https://www.ncbi.nlm.nih.gov/pubmed/22253748 http://dx.doi.org/10.1371/journal.pone.0029622 |
Ejemplares similares
-
Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
por: Zhou, Jun, et al.
Publicado: (2011) -
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014) -
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018) -
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018) -
OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker
por: Min, Le, et al.
Publicado: (2019)